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PURPOSE: Losartan, an angiotensin II receptor blocker, can reduce desmoplasia and enhance drug delivery and efficacy
through improving interstitial transportandvascularperfusion inpancreaticductal adenocarcinoma (PDAC)models inmice.The
purpose of this study was to determine whether magnetic resonance imaging (MRI) of magnetic iron oxide nanoparticles
(MNPs) and micro–positron emission tomography (PET) measurements could respectively detect improvements in tumor
vascular parameters and drug uptake in orthotopic PDAC in mice treated with losartan. METHOD AND MATERIALS: All
experiments were approved by the local Institutional Animal Care and Use Committee. FVBmice with orthotopic PDACwere
treated daily with an i.p. injection of losartan (70mg/kg) or saline (control vehicle) for 5 days. In order to calculate the fractional
blood volume, vessel size index, and vessel density index, MRI was performed at 4.7 T following the injection of 3mg/kg iron
ferumoxytol (i.v.).DynamicPET imageswerealsoacquired for60minutesusingan 18F-5FU tracerdoseof200μCiandanalyzed
for time activity curves normalized to muscle. Statistical analyses compared both cohorts using an unpaired two-tailed t test.
RESULTS: In comparison to the control treatment, the losartan administration significantly increased the fractional blood
volume (mean ± SEM) [12.1 ± 1.7 (n = 19)vs6.7 ± 1.1 (n = 20);P b .02] andvessel size index (128.2 ± 35.6vs57.5 ± 18;
P b .05). Losartan also induceda significant increase in the intratumoral uptakeof 18F-5FUby53% (P b .0001).CONCLUSION:
MRI using FDA-approvedMNPs provides a noninvasive, translatablemeans of assayingmicrovascular parameters induced by
losartan in pancreatic cancer. PET measurements demonstrated that losartan significantly increased the uptake of 18F-5FU.
Translational Oncology (2016) 9, 431–437Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a devastating illness
that responds poorly to chemotherapy. The poor survival of patients
with unresectable PDAC is partly due to the fact that extant
chemotherapeutic options have dismal efficacy in humans [1,2]. In
PDAC, the desmoplastic reaction rich in extracellular matrix
constituents like collagen fibers and hyaluronan is a significant
barrier, which limits the therapeutic efficacy of cytotoxic agents
[3–5]. The solid pressure/stress produced by the dynamic interaction
between cancer cells, stromal cells, and the extracellular matrix








432 PET/MRI of losartan in pancreatic cancer models Kumar et al. Translational Oncology Vol. 9, No. 5, 2016drug delivery [3,6–8]. In PDAC models, stromal modifiers, which
reduce desmoplasia, can improve vascular perfusion, drug delivery,
and the effectiveness of cytotoxic agents [3–5,9]. In a transgenic mice
model of PDAC, PEGPH20, a recombinant enzyme which degrades
hyaluronan, reduced the hyaluronan content and enhanced vascular
perfusion and the efficacy of gemcitabine [5]. We have shown that
the angiotensin II receptor blocker losartan—which inhibits the
activity of TGF-β and other profibrotic cytokines—reduces the levels
of collagen and hyaluronan in orthotopic PDAC models [3,10].
Furthermore, losartan increased the fraction of perfused vessels and
the delivery and efficacy of 5-fluorouracil (5FU) [3]. Losartan also
increased the efficacy of the nanotherapeutic Doxil [10]. Interest-
ingly, the administration of 5FU, Doxil, or losartan alone did not
affect the growth of pancreatic tumors, but tumors were significantly
smaller in mice treated with losartan combined with either Doxil or
5FU [3,10]. Thus, losartan shows potential as an adjunct to safely
enhance the intratumoral penetration and efficacy of small and large
therapeutics in patients with pancreatic cancer. Losartan combined
with the folinic acid (leucovorin), fluorouracil (5-FU), irinotecan
(Camptosar), oxaliplatin (Eloxatin) (FOLFIRINOX) cocktail is now
being evaluated in patients with locally advanced unresectable
pancreatic cancer (NCT01821729).
An unmet need in clinical imaging is a noninvasive, translatable
approach to measure microvascular changes in humans. The
malignant neovasculature has been shown to be hyperpermeable to
molecules [11–22]. Due to this hyperpermeability, Dynamic
contrast-enhanced magnetic resonance imaging (MRI) with
Gadolinium - diethylenetriaminepentaacetic acid (Gd-DTPA)
provides a noninvasive, quantitative measure (e.g., Ktrans) of
response to novel antiangiogenic drugs in hypervascular malignan-
cies [11–22]. Blood vessel density, however, is known to be
markedly lower in PDAC [4], which may explain its poor response
to antiangiogenic therapies and which makes PDAC a poor choice
for interrogation with dynamic techniques. Because of its long
intravascular blood pool resident time, MRI with magnetic
nanoparticles (MNPs) is a better imaging method for PDAC
because it offers a steady-state solution for precise measurements of
microvascular parameters [23–26]. Steady-state techniques are also
ideally suited to study PDAC in humans because respiratory
motion and luminal gas surrounding the pancreas severely limit
dynamic techniques. We and others have shown in xenograft
models implanted subcutaneously that MRI of MNPs provides a
noninvasive, accurate assessment of fractional blood volume (fBV)
and vessel size index (VSI) [24–34].
The poor efficacy of chemotherapy in PDAC concomitant with
the exciting potential of increased drug uptake induced by
angiotensin II receptor blocker (ARB) in a PDAC model represents
a challenge for noninvasive imaging methods assessing tumor
vascular parameters and drug delivery in preclinical and human
tumors. The goal of this study was to determine whether MRI with
MNPs is a valid noninvasive, steady-state surrogate biomarker of
the functional neovasculature in an orthotopic mouse model of
PDAC. We determined the relationship of the steady-state shifts
ΔR2 and ΔR2* in the transverse relaxation rates 1/T2 and1/T2* caused by
injection of long circulating MNPs by modeling the fBV (~ΔR2*), VSI
(~ΔR2*/ΔR2)n, and vessel density index (VDI) [ΔR2/(ΔR2*)n] [24–34].
Given the low vascular density in PDAC,morphologic indices such as fBV,
VSI, and VDI may be more insightful measures of indirect effects on the
tumor vasculature than measurements derived from dynamic approaches(e.g., Ktrans). We also hypothesize that MRI will be sensitive to
losartan-induced changes in the PDAC vasculature. Furthermore, we
hypothesize that changes in the PDAC vasculature are linked to changes in
drug delivery as determined by micro–positron emission tomography
(PET) measurements of 18F-5FU uptake.
Materials and Methods
Drug Preparation
Losartan pills (50 mg/pill) (Merck Pharmaceuticals, Inc.. Kenilworth,
NJ)—obtained from the Massachusetts General Hospital pharmacy—
were crushed and dissolved in PBS over 24 hours as previously described
[3,10]. The solutions were then sterile filtered for injection.
Animal Model and Tumor Treatment Protocol
All experiments were approved by the Massachusetts General
Hospital Institutional Animal Care and Use Committee. AK4.4 cells
were originally isolated from the PDAC lesions of a genetically
engineered mouse model (Ptfl-Cre/LSL-KrasG12D/p53Lox) [35].
Orthotopic tumors were generated by implanting 1-mm3 chunks of
AK4.4 in the pancreas of 6- to 8-week-old FVB mice. Mice with
AK4.4 tumors were separated into two groups (losartan and control).
Animals were treated daily with an intraperitoneal (i.p.) injection of
losartan (70 mg/kg) or saline (control) for 5 days. Animals were
sacrificed after a 5-day course of treatment and imaging.
Magnetic Resonance Imaging
MRI was performed at 4.7 T on a Bruker imaging system (Biospin,
Karlsruhe, Germany). Animals were imaged after 5 days of therapy.
Animals were anesthetized during imaging with 1% to 1.5% inhaled
isoflurane and monitored during imaging with respiratory monitor-
ing. Imaging protocols included a Tri-plane and axial RARE localizer.
Multislice multiecho T2-weighted imaging was performed prior to
and following intravenous injection of MNPs (10 mg/kg Fe,
ferumoxytol, Feraheme; AMAG Pharma, Waltham, MA). The
following parameters were utilized: Multiecho spin echo T2 maps
were acquired with the following parameters: flip angle =90°; matrix
size = 128 × 64; repetition time (TR) = 2000 milliseconds; echo time
(TE) = 6 equally spaced echoes at 10-millisecond intervals ranging
from 10 to 60 milliseconds; field of view (FOV) = 4.24 × 2.12 cm;
slice thickness = 1 mm. Multiecho gradient echo T2* maps were
acquired with the following parameters: flip angle =60°; matrix size =
128 × 128; TR = 750 milliseconds; TE = 4 equally space echvoes at
5 msec; FOV = 4.24 × 2.12 cm; slice thickness = 1 mm.
T1-weighted imaging was performed following the administration
of intravenous Gd-DTPA utilizing the following parameters: flip
angle =90°; matrix size = 256 × 256; TR = 700 milliseconds; TE =14
milliseconds; FOV = 4.24 × 2.12 cm; slice thickness = 1 mm.
MRI Data Analysis
All data were analyzed in Matlab using code written in-house.
fBV, VSI, and VDI values were obtained by defining a region of
interest (ROI) over the entire tumor area. This process was repeated
for three central slices of the tumor for every animal, and the mean value
within the ROI was calculated. T2 and T2* values were obtained using
gradient echo (GRE) and spin echo (SE) data, respectively, by plotting
mean ROI value at each echo and calculating the best-fit exponential decay
function. R2 andR2*were defined as the inverse of T2 or T2* values;ΔR*2
and ΔR2were calculated as the ratio of values before and after iron contrast
injection.
Figure 1. T1-weighted axial MR images of mice status postimplantation of AK4.4 orthotopically in the tail of the pancreas, with
pseudocolorized maps of fBV (A, B) overlying the tumors. These maps were obtained after injection of the ferumoxytol, the FDA-approved
nanoparticle. Note the increased distribution of fBV in the losartan-treated animals (B) as compared to controls (A). Histogram analysis
demonstrates a right shift in pixels as obtained from ROI analysis within the central slice of the losartan-treated animals in fBV (D). ROI
analysis of the three central slices was performed in all animals. The bar graphs demonstrate a nearly two-fold increase in fBV (C) (P b .02)
in losartan-treated animals (n = 19) (mean ± SEM) (12.1 ± 1.7) compared to the control group (n = 20) (6.7 ± 1.1) (P b .02).
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where fBVmuscle is assumed to be a constant of 3%.
VSI was computed using the following equation:




For normalized value calculations, the first two terms were considered
to be constant for all images and were therefore disregarded.
VDI was computed as follows:
VDI ¼ 329ΔR2
ΔR2
As for the VSI calculations, the first term in the VDI equation was
disregarded during calculation of normalized values [33].Paramagnetic maps were generated by calculating VSI, VDI, and
fBV values on a voxel-by-voxel basis. Histograms were obtained by
plotting vessel indices within a tumor ROI against the frequency of
occurrence.
Data are reported as fBV, VSI, and VDI ± standard error of the mean.Positron Emission Tomography
MicroPET studies were performed on a Triumph PET/CT
Scanner (GE Medical Systems, Waukena, WI). A separate trial was
performed using the identical animal model and treatment protocol
in order to assess whether losartan demonstrated increased
drug delivery as measured by 18F-5FU using dynamic imaging
over 1 hour. These experiments were performed on separate
days and used control and treated pairs in order to minimize
scanner and radioisotope production bias. N = 5 pairs
of orthotopic pancreatic tumor model mice were anesthetized
using isoflurane and imaged in treated-control pairs. Dynamic PET
images were acquired for 60 minutes using an 18F-5FU tracer
dose of 200 μCi per animal. Computed tomographic (CT) scans for
attenuation and anatomic co-registration were performed
immediately following PET acquisition. ROI analysis was
performed on dynamic co-registered images using Osirix with
time activity curves normalized to muscle. Initial area under the
curve was performed on normalized curves and then compared to
controls.
Figure 2. T1-weighted axial MR images of mice status postimplantation of AK4.4 orthotopically in the tail of the pancreas, with
pseudocolorized maps of fractional blood volume (VSI) (A, B), and VDI (E, F) overlying the tumors. These maps were obtained after
injection of the ferumoxytol, the FDA-approved nanoparticle. Note the increased distribution of VSI in the losartan-treated animals (B) as
compared to controls (A). In addition, note the decrease in VDI in the losartan-treated animal (D) as compared to the control (C). Histogram
analysis demonstrates a right shift in pixels as obtained from ROI analysis within the central slice of the losartan-treated animals in VSI (D)
and a left shift of pixels in VDI (F). Histogram analysis (C) demonstrates a shift in VSI in losartan-treated animals as compared to control,
and ROI analysis of the central three slices demonstrated a significant increase in VSI (128.2 ± 35.6 vs 57.5 ± 18) (P b .05) in losartan
than control animals.
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Statistical analyses of MRI data compared both cohorts losartan
(n = 19) and control (n = 20) using an unpaired two-tailed t test of
unequal variances. Analysis of PET data (n = 5 pairs) were performed
using a two-tailed paired t test of unequal variances.
Results
Magnetic resonance imaging (MRI)
Figure 1 demonstrates pseudocolorized fBV (A and B) super-
imposed over T1-weighted postcontrast images at the middle level of
orthotopic tumors, in the region near the tail of the pancreas. Note
the heterogeneous increase in fBV in the losartan-treated cohort
(Figure 1B) in comparison to the saline-treated cohort (Figure 1A).
ROI analysis of the three central slices of each tumor demonstrated a
nearly two-fold significant increase in fBV (P b .02) in
losartan-treated cohort (mean ± SEM) (12.1 ± 1.7, n = 19) com-
pared to control (6.7 ± 1.1, n = 20) (Figure 1C). This is
corroborated by histogram analysis (Figure 1D) of the fBV data
demonstrating a shift to the right in the losartan-treated cohort
compared to control.
Similarly, we found a heterogeneous increase in VSI in losartan-treated
compared to control mice (Figure 2, A and B). Histogram analysis
(Figure 2C) demonstrates a shift in VSI in losartan-treated animals as
compared to control, and ROI analysis of the central three slicesdemonstrated a significant increase (P b .05) in VSI (128.2 ± 35.6 vs
57.5 ± 18) in losartan versus control animals.
Paradoxically, there was an increase in VDI visually in the
pseudocolorized VDI map in the control-treated (Figure 2E) cohort
as compared to the losartan-treated cohort (Figure 2F), most notable
in the periphery than the tumor center. This was also replicated in the
histogram analysis (Figure 2G), and when performing the quantitative
ROI analysis, the VDI was significantly higher (P b .05) in control-
(0.15 ± 0.06) than losartan- (0.04 ± 0.01) treated animals.
Losartan Increases Drug Delivery in Orthotopic PDAC
18F-5FUmicroPETwas performed in losartan-treatedmice and paired
control mice (n = 5 pairs) in order to minimize and remove bias from
radioisotope production and attenuation correction. Figure 3 demon-
strates attenuated correctedmicroPET images in control- (Figure 3A) and
losartan-treated (Figure 3B) tumors 60 minutes after the injection of
18F-5FU. Figure 3C is a representative T1-weighted postcontrast image
with a large, enhancing tumor anterior to the left kidney. ROI analysis of
fused CT images was performed on kinetic data acquired at the midpoint
of the tumor, liver, muscle, kidney, and spleen. Kinetic curves are shown
for the tumor in the losartan-treated (red) versus control-treated (blue)
animals. The area under the curve analysis demonstrated a significant
increase (~53%) in 5FU delivery within the tumor of losartan-treated
animals (P b .001, Figure 3E). Losartan did not affect the uptake of
18F-5FU in the liver (Figure 3F), kidney, muscle, or spleen.
Figure 3.MicroPET images after injection of 200 μCi of 18F-5FU of two mice status post orthotopic implantation of PDAC anterior to the
left kidney [(A) control and (B) losartan] treated for 5 days i.p. ROIs are overlying the tumor from CT images.(C) A representative example of
the tumor is shown from a T1-weighted image at 4.7 T status post i.v. injection of Gd-DTPA. (D) Average (n = 5) time activity curves for
uptake from an ROI overlying the entirety of the tumor normalized tomuscle activity. Note the~50% increase (red area under the curve) in
activity in the losartan-treated cohort as compared to the control-treated cohort (blue). (E) Area under the curve analysis of tumor activity
normalized to muscle activity in n = 5 animals. Statistical analysis of the studies using a paired t test (P .001) demonstrates an
approximately 53% increase in drug delivery in the losartan-treated animal cohorts compared to control.
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MRI provides high–spatial resolution, noninvasive imaging of
anatomy with high soft tissue contrast. Dynamic contrast-enhanced
MRI techniques with the small molecule gadolinium-based contrast
agents are sensitive to changes in the tumor microvasculature but have
limited applicability in the human pancreas because of motion and
overlying gas [24–34]. Steady-state techniques using magnetic
nanoparticles provide a noninvasive, accurate, and sensitive assess-
ment of fBV, which was considered a surrogate marker of microvessel
density in subcutaneous pancreatic tumor xenografts [23–26]. This
study expands on these previous studies and shows that MRI of
MNPs is a noninvasive and valid approach to quantify microvascular
parameters in orthotopic PDAC lesions.
Our findings demonstrate that MR measurements of MNPs can
measure changes in fBV, VSI, and VDI induced by the ARB losartan
[26,30,32,34]. Losartan significantly increased the fBV and VSI by
approximately two-fold. In the same orthotopic AK4.4 PDAC
model—based on measurements in histological sections—we found
that losartan significantly increased the fractions of both perfused
vessel and vessels with an open lumen [3,10]. The increased fBV
induced by losartan could result from the increased fraction of
perfused vessels and vessels with larger lumens. The lack of
measurement of the apparent diffusion coefficient limits the accuracy
of VSI measurements [32,34]. However, as mentioned above,
losartan significantly increased the fraction of vessels with an openlumen [3], which supports our MRI estimates of VSI that also
increased following losartan. The significant decrease in VDI could be
due to the higher dose of losartan (70 mg/kg) in comparison to the
lower dose of losartan (40 mg/kg) in our previous study [3]. In other
studies, the genetic deletion of AT1R and high doses of ARBs or
losartan significantly reduced the tumor microvessel density [36,37].
Thus, MR measurements of FDA-approved magnetic nanoparticles
represent a valid approach to interrogate noninvasively the pancreatic
tumor microvasculature in pancreatic cancer patients.
Our microPET measurements demonstrate that, in comparison to
the control group, losartan significantly increased the intratumoral
uptake of 18F-5FU by 53%, which is comparable to the 74% increase
in 5FU uptake measured by reverse-phase high-performance liquid
chromatography with tandem mass spectrometry in orthotopic
AK4.4 tumors [3]. Furthermore, similar to our previous findings
[3], losartan did not affect the uptake of 18F-5FU in the liver, kidney,
muscle, or spleen. Given the improved efficacy of the FOLFIRINOX
cocktail—which includes the drug 5FU—in patients with pancreatic
cancer and our results demonstrating improved drug delivery with
two different methodologies, at different scales, the translatable aspect
of microPET 18F-5FU measurements is important.
There are potential shortcomings with in vivo drug uptake
measurements based on 18F-5FU. 5FU rapidly metabolizes in
plasma, and therefore, since it could not be assayed, it is unclear
which metabolite of 5FU was measured by microPET in tumors.
436 PET/MRI of losartan in pancreatic cancer models Kumar et al. Translational Oncology Vol. 9, No. 5, 2016Because both losartan and control mice were treated and imaged in
pairs and ARBs are not known to increase the metabolism of 5FU, it
is assumed that the metabolism was equivalent in both losartan and
control mice.
In summary, we demonstrate that MRI and microPET can
measure changes in vascular parameters and drug uptake induced by
losartan in a pancreatic cancer model. Our MRI findings support the
hypothesis that ARBs increase the functional microvasculature and,
more importantly, that MRI of magnetic nanoparticles is sensitive to
these changes. Because microPET and high-performance liquid
chromatography measured comparable values of drug uptake,
microPET and MRI represent in vivo approaches that can measure
the changes in the PDAC microenvironment produced by stromal
modifiers. Furthermore, our findings suggest that MRI and
microPET measurements can be readily translated to patients with
pancreatic cancer.
Paradoxically, there was an increase in VDI visually in the
pseudocolorized VDI map in the control-treated (E) cohort as
compared to the losartan-treated cohort (F), most notable in the
periphery as compared to the central tumor. This was also replicated
in the histogram analysis (G), and when performing quantitative ROI
analysis, the losartan-treated animals (0.04 ± 0.01) were lower in
VDI as compared to the control animals (0.15 ± 0.06) (P b .05).
Translational Relevance: In pancreatic ductal adenocarcinoma
(PDAC), the interaction between the desmoplastic stroma and cancer
cells generates physical forces that compress microvessels, thus
reducing vascular perfusion and the delivery of therapeutics. We
have shown that the angiotensin II receptor blocker losartan reduces
desmoplasia and improves vascular perfusion and drug uptake in
PDAC models. Magnetic resonance imaging (MRI) using FDA-ap-
proved magnetic nanoparticles and positron emission tomography
(PET) are robust steady-state technique that, unlike intravital
microscopy or histologic measurements, are readily translatable to
humans and scalable from mice to humans. The aim of this study was
to refine and apply MRI- and microPET-based methods to
noninvasively measure changes in microvascular parameters and
drug uptake (18F-5-fluorouracil) in a murine model of PDAC in
response to losartan. We show here that MRI and microPET
approaches detect increases in microvascular parameters and drug
uptake induced by losartan. Our results suggest that MRI and
microPET techniques are readily translatable to human and could be
used to determine the effects of stromal modifiers in the lesions of
pancreatic cancer patients.
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